CPI-203
CAS No. : 1446144-04-2
| Size | Price | Stock |
|---|---|---|
| 2mg | $60 | In-stock |
| 5mg | $110 | In-stock |
| 10mg | $175 | In-stock |
| 25mg | $380 | In-stock |
| 50mg | $600 | In-stock |
| 100mg | $950 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15846 |
| M.Wt: | 399.90 |
| Formula: | C19H18ClN5OS |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 47 mg/mL |
CPI-203 is a novel potent, selective and cell permeable inhibitor of BET bromodomain, with an IC50 value of appr 37 nM (BRD4 α-screen assay). IC50 & Target: IC50: 37 nM (BRD4) In Vitro: CPI-203 inhibits BRD4 in vitro and in cells, but does not affect BRD4 kinase activity in vitro[1]. CPI-203 exerts a cytostatic effect in all the 9 MCL cell lines analyzed with GI50 ranging from 0.06 to 0.71 μM, with low cytotoxicity in normal PBMCs from healthy donors. Furthermore, CPI-203 efficiently activates the cell death program in MCL cells[2]. In Vivo: CPI-203 (2.5 mg/kg, i.p.) combined with lenalidomide, enhances the antitumoral properties of each single agent via the abrogation of MYC and IRF4 expression and the induction of apoptosis in n REC-1 tumor-bearing mice[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- CPI-203
- Cat. No.:
- HY-15846
- Quantity:
Your information is safe with us.